Background: Metastatic castration-resistant prostate cancer (mCRPC) has a five-year survival rate of 30% despite the availability of expensive therapeutic agents. This study investigated the costs to a tertiary public hospital of the management of mCRPC with various therapeutic agents.
Methods: Between 1 January 2017 and 24 November 2019 the records of patients who were diagnosed with mCRPC and received chemotherapy (docetaxel) in combination with goserelin (a luteinising hormone-releasing hormone [LHRH]), or bicalutemide (an anti-androgen) at the Inkosi Albert Luthuli Central Hospital were analysed. The activity-based costing (ABC) model was used to calculate the medicine costs and other expenses incurred by the hospital.
Results: During the study period, 64 patients, mean age 66 years (± 8.7) at first visit, met the inclusion criteria of this study. The total cost incurred by the hospital was R10 338 559. On average, a total of R161 540 (SEM R22 699.00) per patient was incurred by the hospital. There was 60% reduction ( = 0.01), after the average period of 4 months (± 2.9), in PSA levels in patients who received goserelin monotherapy.
Conclusion: The therapeutic gain from extremely expensive therapy in mCRPC patients requires evaluation of clinical response and survival data to justify the expense.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Outcomes and efficacy of robotic-assisted radical prostatectomy using the CMR Versius platform: a prospective study on 118 patients with 1-year follow-up.
Int Urol Nephrol
January 2025
Department of Urology, Faculty of Medicine, Cairo University, Cairo, Egypt.
Objective: To evaluate the outcomes and efficacy of robot-assisted radical prostatectomy (RARP) using the Versius robotic surgical system, aiming to provide comprehensive data on perioperative outcomes, postoperative recovery, and complications.
Patient And Methods: All cases of RARP using the CMR Versius platform performed at Cairo University Hospital over a two-year period were enrolled in this study. All patients had pathologically confirmed prostate cancer in both localized and locally advanced stages.
A comprehensive insights of cancer immunotherapy resistance.
Med Oncol
January 2025
Department of In Vivo Pharmacology, TCG Lifesciences Pvt. Ltd, BN 7, Sector V, Salt Lake City, Kolkata, West Bengal, 700091, India.
Cancer is a major global health issue that is usually treated with multiple therapies, such as chemotherapy and targeted therapies like immunotherapy. Immunotherapy is a new and alternative approach to treating various types of cancer that are difficult to treat with other methods. Although immune checkpoint inhibitors have shown promise for long-term efficacy, they have limited effectiveness in common cancer types such as breast, prostate, and lung.
View Article and Find Full Text PDFIncisional PSMA PET/CT-positive recurrences in prostate cancer- is there an implication on clinical care?
Clin Exp Metastasis
January 2025
Martini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Hamburg, Germany.
Oligorecurrent prostate cancer (PCa) can be treated with metastasis-directed therapy (MDT), which may be performed using radioguided surgery (RGS) as an experimental approach. These procedures have shown promising outcomes, largely due to the high lesion detection rate of positron emission tomography/computed tomography (PET/CT). We present a case series of patients who underwent RGS following robot-assisted radical prostatectomy (RARP).
View Article and Find Full Text PDFTalazoparib plus enzalutamide versus placebo plus enzalutamide for patients with advanced prostate cancer and changes in specific DNA repair genes: a plain language summary of the results from the TALAPRO-2 study.
Future Oncol
January 2025
uHuntsman Cancer Institute (NCI-CCC), University of Utah, Salt Lake City, UT, USA.
Incidence and Risk of Thromboembolic and Cardiovascular Adverse Events with PARP Inhibitor Treatment in Patients with Metastatic Castration-resistant Prostate Cancer: A Systematic Review and Safety Meta-analysis.
Eur Urol Open Sci
February 2025
Department of Medical Oncology, IRCCS San Raffaele Hospital, Milan, Italy.
Background And Objective: PARP inhibitor (PARPi) treatment is an effective option for patients with metastatic castration-resistant prostate cancer (mCRPC). There are few data on the cardiovascular and thromboembolic safety of these agents in mCRPC, as cardiovascular and thromboembolic adverse events (AEs) are uncommon. Our aim was to analyze the incidence and risk of major adverse cardiovascular events (MACEs), thromboembolic events, and hypertension with PARPi therapy in mCRPC.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!